Describing themselves as developing technologies and small molecules to fight human disease, the Bioog314 business model is then to license these inventions to partners for development into therapeutic products. With professional ties to Columbia University Medical center, principals indicate having worked (August 2020) on over ten scientific programs - ranging from being in discovery status phase through clinical trials, areas of interest are defined as encompassing areas of investigation from chronic pain and age-related macular degeneration to diabetes.
